R26
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- ANGIOGENESIS+0.420
- MYC_TARGETS_V1+0.420
- E2F_TARGETS+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- HEDGEHOG_SIGNALING+0.330
- GLYCOLYSIS+0.310
- G2M_CHECKPOINT+0.300
- HYPOXIA+0.270
- MTORC1_SIGNALING+0.260
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INTERFERON_GAMMA_RESPONSE-0.440
- IL6_JAK_STAT3_SIGNALING-0.300
- PROTEIN_SECRETION-0.220
- PI3K_AKT_MTOR_SIGNALING-0.200
- TGF_BETA_SIGNALING-0.190
- COMPLEMENT-0.180
- PEROXISOME-0.150
- KRAS_SIGNALING_UP-0.140
- ALLOGRAFT_REJECTION-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516100 | — | — | 0.863 |
| 2 | TCGA-85-6798-01A-11R-1949-07 | — | cohortSQ2 | 0.843 |
| 3 | SRR10899997 | — | — | 0.821 |
| 4 | 56218_S133 | — | cohortSQ1 | 0.819 |
| 5 | TCGA-85-A4CN-01A-11R-A24H-07 | — | cohortSQ2 | 0.812 |
| 6 | TCGA-34-5236-01A-21R-1820-07 | — | cohortSQ1 | 0.806 |
| 7 | TCGA-22-5482-01A-01R-1635-07 | — | cohortSQ2 | 0.805 |
| 8 | SRR8518158 | — | E | 0.801 |
| 9 | R156 | — | — | 0.789 |
| 10 | TCGA-58-8391-01A-11R-2326-07 | — | cohortSQ2 | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |